To explore the therapeutic potential of cell-specific NO/cGMP mechanisms in cardiac recovery from myocardial ischemia and sudden cardiac arrest.
In the Ichinose lab in Boston, the doctoral researchers will be trained in
- the cardiac arrest and cardiopulmonary resuscitation model (CA/CPR),
- different invasive and non-invasive methods for assessing right (and left) ventricular function, and
- the therapeutic application of inhaled nitric oxide.
In a first step, they will also attempt to prove the translational potential of our animal based work by testing promising cGMP-elevating drugs (which will be made available by Bayer and Ironwood) in failing human cardiomyocytes and non-cardiomyocytes, which are available in the Ichinose lab. Following the technical guidance in Boston, CA/CPR experiments will then be performed in cell-type specific mutants.
Melanie Cruz Santos studied pharmacy at the University of Tübingen and obtained her approbation as a pharmacist in 2017. During her pharmaceutical studies and her practical year, she developed a growing interest in physiological signaling pathways and their significance under pathophysiological conditions, leading her to subsequently complete a Master's degree in Pharmaceutical Sciences and Technologies with a focus on cardiovascular research at the University of Tübingen. A combination of her specific interests encouraged her to start her doctoral studies in Robert Lukowski's laboratory, where she investigates the therapeutic potential of cell-specific NO/cGMP mechanisms in cardiac recovery from myocardial ischemia and sudden cardiac arrest.
Frankenreiter S, Bednarczyk P, Kniess A, Bork N, Straubinger J, Koprowski P, Wrzosek A, Mohr E, Logan A, Murphy MP, Gawaz M, Krieg T, Szewczyk A, Nikolaev VO, Ruth P, Lukowski R. cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation. 2017;doi: 10.1161/CIRCULATIONAHA.117.028723
Straubinger J, Boldt K, Kuret A, Deng L, Krattenmacher D, Bork N, Desch M, Feil R, Feil S, Nemer M, Ueffing M, Ruth P, Just S, Lukowski R. Amplified pathogenic actions of angiotensin II in cysteine-rich LIM-only protein 4 negative mouse hearts. FASEB J. 2017;31:1620-38